Published in J Virol on September 05, 2007
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol (2008) 5.26
Complete genome sequences of avian paramyxovirus serotype 6 prototype strain Hong Kong and a recent novel strain from Italy: evidence for the existence of subgroups within the serotype. Virus Res (2010) 1.29
Identification of a broad-spectrum arenavirus entry inhibitor. J Virol (2008) 1.23
The curious case of arenavirus entry, and its inhibition. Viruses (2012) 1.11
Human endogenous retrovirus HERV-K(HML-2) encodes a stable signal peptide with biological properties distinct from Rec. Retrovirology (2009) 0.93
Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike. PLoS Pathog (2016) 0.90
Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV. Nat Struct Mol Biol (2016) 0.87
Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy. PLoS One (2014) 0.83
Characterization of Lassa virus glycoprotein oligomerization and influence of cholesterol on virus replication. J Virol (2009) 0.82
Genomic analysis and pathogenic characteristics of lymphocytic choriomeningitis virus strains isolated in Japan. Comp Med (2012) 0.80
Arenavirus stable signal peptide is the keystone subunit for glycoprotein complex organization. MBio (2014) 0.79
The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry. J Virol (2012) 0.77
Bunyamwera orthobunyavirus glycoprotein precursor is processed by cellular signal peptidase and signal peptide peptidase. Proc Natl Acad Sci U S A (2016) 0.76
Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem (1987) 59.79
Signal sequences. The limits of variation. J Mol Biol (1985) 21.24
Intracellular protein topogenesis. Proc Natl Acad Sci U S A (1980) 13.40
The signal peptide. J Membr Biol (1990) 7.94
Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim Biophys Acta (1999) 6.98
Protein translocation across the endoplasmic reticulum. Cell (1984) 6.69
Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science (1998) 5.83
A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci U S A (1994) 4.86
Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science (2002) 4.39
The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc Natl Acad Sci U S A (2003) 3.34
Signal sequences: more than just greasy peptides. Trends Cell Biol (1998) 3.18
Predicting the topology of eukaryotic membrane proteins. Eur J Biochem (1993) 2.73
Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J Virol (2003) 2.57
Mechanism of lymphocytic choriomeningitis virus entry into cells. Virology (1994) 1.93
Complete sequence of the S RNA of lymphocytic choriomeningitis virus (WE strain) compared to that of Pichinde arenavirus. Virus Res (1985) 1.92
Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Rep (2003) 1.85
Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology (1995) 1.77
The signal peptide of the Junín arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex. J Virol (2004) 1.74
Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol (2002) 1.74
Biochemistry, molecular biology, and genetics of the oligosaccharyltransferase. FASEB J (1996) 1.72
Acidic pH triggers LCMV membrane fusion activity and conformational change in the glycoprotein spike. Virology (1994) 1.70
A new class of fusion-associated small transmembrane (FAST) proteins encoded by the non-enveloped fusogenic reoviruses. EMBO J (2000) 1.66
Signal peptide of Lassa virus glycoprotein GP-C exhibits an unusual length. FEBS Lett (2003) 1.62
Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization. Virology (1983) 1.49
Dual topology of the hepatitis B virus large envelope protein: determinants influencing post-translational pre-S translocation. J Biol Chem (2001) 1.43
Arenaviruses: protein structure and function. Curr Top Microbiol Immunol (2002) 1.38
Protein targeting signals. Curr Opin Cell Biol (1990) 1.36
Reptilian reovirus utilizes a small type III protein with an external myristylated amino terminus to mediate cell-cell fusion. J Virol (2004) 1.32
Role of the stable signal peptide and cytoplasmic domain of G2 in regulating intracellular transport of the Junín virus envelope glycoprotein complex. J Virol (2006) 1.31
Glycosylation efficiency of Asn-Xaa-Thr sequons depends both on the distance from the C terminus and on the presence of a downstream transmembrane segment. J Biol Chem (2000) 1.25
High-level transient expression of influenza virus proteins from a series of SV40 late and early replacement vectors. Gene (1988) 1.24
Bitopic membrane topology of the stable signal peptide in the tripartite Junín virus GP-C envelope glycoprotein complex. J Virol (2007) 1.19
Recombinant expression of lymphocytic choriomeningitis virus strain WE glycoproteins: a single amino acid makes the difference. J Virol (2001) 1.18
Long-lived signal peptide of lymphocytic choriomeningitis virus glycoprotein pGP-C. J Biol Chem (2003) 1.18
Snapshots of membrane-translocating proteins. Trends Cell Biol (1996) 1.12
Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains. J Virol (2007) 1.09
Lassa virus glycoprotein signal peptide displays a novel topology with an extended endoplasmic reticulum luminal region. J Biol Chem (2004) 1.06
The N-terminus of B96Bom, a Bombyx mori G-protein-coupled receptor, is N-myristoylated and translocated across the membrane. FEBS J (2005) 0.85
Protein insertion into the membrane of the endoplasmic reticulum: the architecture of the translocation site. Cold Spring Harb Symp Quant Biol (1995) 0.80
Conformational control through translocational regulation: a new view of secretory and membrane protein folding. Bioessays (2002) 0.77
Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J Virol (2003) 2.57
Resistance of mature T cells to oncogene transformation. Blood (2008) 2.32
Distinct targeting pathways for the membrane insertion of tail-anchored (TA) proteins. J Cell Sci (2008) 2.11
Distinct modes of signal recognition particle interaction with the ribosome. Science (2002) 2.08
Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol (2002) 1.74
Signal peptide peptidase (SPP) assembles with substrates and misfolded membrane proteins into distinct oligomeric complexes. Biochem J (2010) 1.68
Structural insights into tail-anchored protein binding and membrane insertion by Get3. Proc Natl Acad Sci U S A (2009) 1.63
Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther (2007) 1.44
Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol (2004) 1.43
WRB is the receptor for TRC40/Asna1-mediated insertion of tail-anchored proteins into the ER membrane. J Cell Sci (2011) 1.30
CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica (2010) 1.30
Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther (2007) 1.29
Asna1/TRC40-mediated membrane insertion of tail-anchored proteins. J Cell Sci (2010) 1.26
Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One (2009) 1.19
Long-lived signal peptide of lymphocytic choriomeningitis virus glycoprotein pGP-C. J Biol Chem (2003) 1.18
A-to-G hypermutation in the genome of lymphocytic choriomeningitis virus. J Virol (2006) 1.18
Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol (2003) 1.16
Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis. Eur J Haematol (2008) 1.15
Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J Virol (2011) 1.06
Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica (2010) 1.06
Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol (2005) 1.06
Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J Virol (2006) 1.03
The structure of Get4 reveals an alpha-solenoid fold adapted for multiple interactions in tail-anchored protein biogenesis. FEBS Lett (2010) 1.03
Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol (2004) 1.03
The signal peptide of the mouse mammary tumor virus Rem protein is released from the endoplasmic reticulum membrane and accumulates in nucleoli. J Biol Chem (2008) 1.00
An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther (2010) 1.00
Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One (2010) 0.99
Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLoS One (2009) 0.96
The influence on the immunomodulatory effects of dying and dead cells of Annexin V. J Leukoc Biol (2006) 0.96
Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins. Hum Gene Ther (2004) 0.95
Signal recognition particle Alu domain occupies a defined site at the ribosomal subunit interface upon signal sequence recognition. Biochemistry (2004) 0.93
EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP. J Immunol (2011) 0.91
Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46. J Virol (2009) 0.90
Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes. Mol Med (2011) 0.88
Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV-1 fusion inhibitory peptide C46. ChemMedChem (2006) 0.88
Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther (2006) 0.88
Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Eur J Immunol (2007) 0.88
Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin Cancer Res (2007) 0.86
Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect. J Mol Med (Berl) (2011) 0.85
Protein scaffold and expression level determine antiviral activity of membrane-anchored antiviral peptides. Hum Gene Ther (2009) 0.85
TK.007: A novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy. Hum Gene Ther (2010) 0.84
Sec61beta, a subunit of the Sec61 protein translocation channel at the endoplasmic reticulum, is involved in the transport of Gurken to the plasma membrane. BMC Cell Biol (2009) 0.84
Complement opsonization enhances friend virus infection of B cells and thereby amplifies the virus-specific CD8+ T cell response. J Virol (2010) 0.83
Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy. J Mol Med (Berl) (2012) 0.83
Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection. Mol Ther (2011) 0.83
VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. J Virol (2014) 0.83
Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1. Mol Ther (2013) 0.82
The Drosophila Crumbs signal peptide is unusually long and is a substrate for signal peptide peptidase. Eur J Cell Biol (2010) 0.80
T cell culture for gammaretroviral transfer. Methods Mol Biol (2009) 0.79
A retroviral packaging cell line for pseudotype vectors based on glioma-infiltrating progenitor cells. J Gene Med (2007) 0.79
Decreased tumor surveillance after adoptive T-cell therapy. Cancer Res (2007) 0.78
A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells. J Med Primatol (2014) 0.78
Simplified generation of high-titer retrovirus producer cells for clinically relevant retroviral vectors by reversible inclusion of a lox-P-flanked marker gene. Mol Ther (2004) 0.78
Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responses. PLoS One (2012) 0.78
A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity. Antimicrob Agents Chemother (2012) 0.76
Comparison of three humanized mouse models for adoptive T cell transfer. J Gene Med (2012) 0.76
C peptides as entry inhibitors for gene therapy. Adv Exp Med Biol (2015) 0.75
Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp). J Clin Virol (2009) 0.75
Cell and virus genetics at the roots of gene therapy, retrovirology, and hematopoietic stem cell biology: Wolfram Ostertag (1937-2010). Hum Gene Ther (2010) 0.75